- Service category
- Pre-clinical development and testing, pre-clinical CRO
Your company? Get access to this profile.
RIKEN Center for Genomic Medicine
By systematic analysis of SNPs covering the entire genome, the Center for Genomic Medicine is investigating genes susceptible to various diseases, including atopic dermatitis, bronchial asthma, myocardial infarction, rheumatoid arthritis, osteoarthritis, diabetic nephropathy, obesity, and Crohn's disease as well as genes related to responses to interferon treatment of hepatitis C infection. To date, we have identified genes involved in the onset of myocardial infarction, rheumatoid arthritis, osteoarthritis, disc herniation, bronchial asthma and diabetic nephropathy.
The results of this research will be applied in the "personalized medicine", where an appropriate medication with the minimum risk of adverse reactions is provided to an individual patient. Furthermore, if we can isolate genes causative to various diseases whose etiology is unknown or little known, such information will be applied to the development of novel molecular-targeting drugs. Moreover, we hope to develop preventive techniques suitable for individuals, through a prior detection of a higher risk to certain diseases.
RIKEN Bioinformatics And Systems Engineering division
Our objective is to deepen our overall understanding of life by analyzing the vast quantities of data produced in the life sciences so as to promote information technology research strategically directed at making higher-order scientific discoveries. We will also work to pioneer the important future science of genome design, and build the bioinformatics infrastructure that is needed to resolve so many of humanity's problems.
A comprehensive analysis of the huge volume of newly produced data together with existing data will be essential for future life science research. The Bioinformatics And Systems Engineering division will organize existing and new data into a database which will be made available to the public for greater convenience of use and continuity. At the same time, we will carry out large-scale analysis of this vast data resource to elucidate biological functions, and pursue informatics research for genome design.
RIKEN Center for Molecular Imaging Science
In July 2005, the Center for Molecular Imaging Science (CMIS) was selected as a research base for exploring new drug candidates as part of the Molecular Imaging Research Program launched by Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT), in an effort to promote research and development in the life sciences to respond to societal needs. As of October 1, 2008, the Center consists of five laboratories and two units which focus their research on 1) using a range of molecular imaging technology, in particular Positron Emission Tomography (PET), to evaluate newly developed molecular probes and their functions, and 2) developing new imaging techniques to analyze molecular dynamics, all with the aim to shorten the pre-clinical phase period in the drug discovery process. As one of the core institutions in the nation-wide network for molecular imaging research, the CMIS is also committed to cultivating the talent of young researchers, who will be the future driving force in this field.
RIKEN Program for Drug Discovery and Medical Technology Platforms
The mission of the RIKEN Program for Drug Discovery and Medical Technology Platforms is to provide pharmaceutical and medical technology companies with platforms that will optimize the application of basic research seeds in drug discovery processes and medical technology innovation. Specifically, this involves forging alliances with private industry so that drug discovery platform units within RIKEN and outside networks can make optimum use of these seeds to lead to new advances in drug discovery and medical technology.
You might be also interested in
Sourcing this company's services?Send inquiry anonymously »